June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 09, 2025

New Fixed-Dose RSV Antibody Approved

The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.

Conexiant

June 06, 2025

RSV or COVID: Which Strains the Heart?

A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.

Conexiant

June 03, 2025

Stopping Antipsychotics May Lower Risks Posthospitalization: Study

Older adults who stopped antipsychotic medications after hospitalization had fewer rehospitalizations, less delirium, and lower mortality, according to a large U.S. study using real-world Medicare data.

Conexiant

May 29, 2025

Long-Term Steroids in COPD Raise Health Risks

A study of over 500,000 patients found that using inhaled corticosteroids for more than 2 years in COPD significantly increased the risk of diabetes, pneumonia, fractures, cataracts, and osteoporosis.

Conexiant

May 28, 2025

Study Finds Low RSV Vaccine Uptake Among Older Adults

A new multicenter analysis of over 6,700 hospitalized older adults found that RSV vaccine uptake was low in its first season, with significant gaps in awareness and access, especially among socioeconomically vulnerable populations.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 20, 2025

ICU Sedation Economics: A $1 Difference

Study finds dexmedetomidine, clonidine, and propofol have comparable cost-effectiveness for critically ill patients on mechanical ventilation.

Conexiant

October 29, 2024

New Data Challenges Pediatric Sinusitis Treatment Guidelines

A JAMA review revealed that only 26% of pediatric ABRS patients treated with placebo required subsequent antibiotic therapy, prompting questions about current guidelines recommending first-line antibiotic use in children with sinusitis.

Conexiant